CANF
USDCan-Fite Biopharma Ltd Sponsored ADR (Israel)
Precio en Tiempo Real
Gráfico de Precios
Métricas Clave
Métricas de Mercado
Apertura
$1.165
Máximo
$1.170
Mínimo
$1.130
Volumen
0.01M
Fundamentos de la Empresa
Capitalización de Mercado
15.8M
Industria
Biotecnología
País
Israel
Estadísticas de Negociación
Volumen Promedio
0.29M
Bolsa
ASE
Moneda
USD
Rango de 52 Semanas
Noticias Relacionadas
Following FDA Compassionate Use Approval for Pancreatic Carcinoma with Can-Fite's Namodenoson, Leading U.S. Medical Centers Seek Authorization for their Patients
Ramat Gan, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
D. Boral Capital analyst Jason Kolbert maintains Can Fite Biofarma with a Buy and maintains $10 price target.
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory
Can-Fite to Generate $685M in Projected Future Revenues from its Partnerships
Ramat Gan, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs for oncological and inflammatory
Can-Fite Reports 2024 Financial Results and Clinical Update
RAMAT GAN, Israel, April 14, 2025 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and
Acciones Relacionadas
Mantente Actualizado
Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.